3D bioprinting: challenges in commercialization and clinical translation

Abstract

3D Bioprinting has become a revolutionary tool in the field of tissue engineering and regenerative medicine. Bioprinting industry has seen a tremendous growth in the past decade, with a number of bioink companies and bioprinter companies on the rise. While the growth of bioprinting has been tremendous in terms of research and reach, permeating into life sciences research where two-dimensional cell culture has been the norm, we are yet to witness a commercial success in terms of clinical translation. This perspective article aims to highlight some of the lesser-discussed challenges in the field that are to be overcome to fully translate the use of bioprinting into the clinics and make it a standard of testing in the pharmaceuticals industry.